Results 231 to 240 of about 1,011,391 (359)

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Clinical Impact of Continuation Versus Cessation of Antiviral Therapy in Chronic Hepatitis B: A Modelling Study With Implications for Hepatitis B Cure. [PDF]

J Viral Hepat
Mohareb AM, Ezaz G, Kim AY, Freedberg KA, Boyd A, Hyle EP.   +5 more
europepmc   +1 more source

Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment

British Journal of Clinical Pharmacology, EarlyView.
Aims Crisugabalin is a novel calcium channel α2δ subunit ligand and a highly selective oral gamma‐aminobutyric acid (GABA) analogue developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN). This study investigated pharmacokinetic properties and safety of crisugabalin in subjects with renal impairment ...
Shibeilei Lin, Ye Wang, Chao Hu, Yanhuan Feng, Xi Tang, Ping Fu, Jia Miao   +6 more
wiley   +1 more source

Hepatic Macrophages in Chronic Hepatitis B: Balancing Immunity and Pathology. [PDF]

Biology (Basel)
Pathania AS, Bhat SA, Adepoju LA, Kharbanda KK, Osna NA.   +4 more
europepmc   +1 more source

Hepatitis B: the immaculate infection.

, 2007
AnnMarie Huysman, Mitul Patel, Douglas T. Dieterich   +2 more
openalex   +1 more source

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim The benzoxaborole derivative DNDI‐6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani, which cause visceral leishmaniasis. We investigated the safety, tolerability and pharmacokinetics of single oral doses of DNDI‐6148 in a randomized, parallel‐group, placebo‐controlled ...
Jean‐Yves Gillon, Sophie Delhomme, Delphine Launay, Séverine Blesson, Stéphanie Braillard, Pegah Maghdooni, Frauke Assmus, Richard Hoglund, Joel Tarning, Sabrina Loyau, Byron Arana, Mathilde Latreille‐Barbier, Yves Donazzolo   +12 more
wiley   +1 more source

Hepatitis B Immunization [PDF]

Journal of Tropical Pediatrics, 2002
openaire   +2 more sources

On the future of therapeutic vaccination in chronic hepatitis B

Future Science OA, 2019
Julio Cesar Aguilar Rubido
doaj   +1 more source

Prevalence of occult hepatitis B infection and hepatitis B genotype characterization among blood donors in Jember Regency, East Java, Indonesia. [PDF]

BMC Infect Dis
Sugiharto VD, Hafza N, Muhammadiy NS, Riyanti R, Cao LC, Huyen DT, My TN, Huyen TTT, Song LH, Senjarini K, Velavan TP.   +10 more
europepmc   +1 more source

Nursing Study of Humanistic Care Combined with Progressive Muscle Relaxation Training for Patients with Hepatitis B Cirrhosis [PDF]

吐 尔逊阿依·买合木提
openalex   +1 more source